No Evidence of XMRV in Prostate Cancer Cohorts in the Midwestern United
Retrovirology 2011, 8:23
Background: Xenotropic murine leukemia virus (MLV)-related virus (XMRV) was initially
identified in prostate cancer (PCa) tissue, particularly in the prostatic stromal fibroblasts, of patients
homozygous for the RNASEL R462Q mutation. A subsequent study reported XMRV antigens in
malignant prostatic epithelium and association of XMRV infection with PCa, especially higher-grade
tumors, independently of the RNASEL polymorphism. Further studies showed high prevalence of
XMRV or related MLV sequences in chronic fatigue syndrome patients (CFS), while others found no,
or low, prevalence of XMRV in a variety of diseases including PCa or CFS. Thus, the etiological link
between XMRV and human disease remains elusive. To address the association between XMRV
infection and PCa, we have tested prostate tissues and human sera for the presence of viral DNA, viral
antigens and anti-XMRV antibodies.
Results: Real-time PCR analysis of 110 PCa (Gleason scores >4) and 40 benign and normal prostate
tissues identified six positive samples (5 PCa and 1 non-PCa). No statistical link was observed between
the presence of proviral DNA and PCa, PCa grades, and the RNASEL R462Q mutation. The amplified
viral sequences were distantly related to XMRV, but nearly identical to endogenous MLV sequences in
mice. The PCR positive samples were also positive for mouse mitochondrial DNA by nested PCR,
suggesting contamination of the samples with mouse DNA. Immuno-histochemistry (IHC) with an
anti-XMRV antibody, but not an anti-MLV antibody that recognizes XMRV, sporadically identified
antigen-positive cells in prostatic epithelium, irrespectively of the status of viral DNA detection. No
serum (159 PCa and 201 age-matched controls) showed strong neutralization of XMRV infection at
Conclusion: The lack of XMRV sequences or strong anti-XMRV neutralizing antibodies indicates no
or very low prevalence of XMRV in our cohorts. We conclude that real-time PCR- and IHC-positive
samples were due to laboratory contamination and non-specific immune reactions, respectively.
You know what, i think WPI should bugger the establishment, just do their own studies and if other groups come online with them then good. I dont think any govt bodies are going to find any positives no matter what. WPI need to do treatment trials with retro positive patients and see what outcomes come from them. The govt has too much to lose by saying cfs has an infectious cause. We are only going to go forward with private organisations like WPI funded by cfs groups/patients etc. I dont think we need govt approval to say cfs is real, when WPI start seeing people recover, govt bodies wont have a choice but to admitt their wrong.
Regarding clinical trials, the WPI might get funding from drug companies, so they won't neccessarily need the government's money (actually, for clinical trials there is a good chance that they won't need it, I think).
I believe most clinical trials are funded by the pharmaceutical companies. The WPI thought GSK would start clinical trials in six months (after the Science paper) but GSK decided to put them aside for the time being and focused on proving XMRV was there. Of course they have an immense amount to gain if XMRV works out.
No offense, but really? You honestly believe this?